Barclays analyst Balaji Prasad raised the firm’s price target on Viatris to $16 from $15 and keeps an Overweight rating on the shares. The analyst says that while company’s 2023 revenue and EBITDA outlook is not a disappointment versus expectations, news on CEO change is a surprise.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VTRS:
